Cancer Research UK and Abcam announce custom antibody partnership
Cancer Research UK (CRUK) and Abcam have announced a new partnership for the development and commercialisation of novel custom antibodies to help accelerate cancer research.
Abcam will develop custom protein-based reagents to targets identified by CRUK-funded researchers.
The resulting antibodies will aid research into cancer biology, help generate new diagnostics tools and potentially form the basis of novel therapies.
Tony Hickson, CBO at Cancer Research UK, said: “We are excited to be partnering with Abcam to expand our access to biological reagents and to create the tools our scientists need to help accelerate our understanding of cancer. Abcam’s antibody development capabilities and ‘end-to-end’ expertise will help provide our researchers with antibody reagents that can be applied from early-stage R&D right through to the clinic.”
Dr John Baker, SVP product portfolio innovation at Abcam, added: “We are proud to be working with Cancer Research UK to support their scientists and to provide them with access to specific and validated reagents to help them achieve their next breakthrough faster.”
The Cambridge Biomedical Campus-based organisations have agreed that Abcam will supply unique antibodies developed within the terms of the agreement to CRUK-funded researchers for an agreed period of exclusivity.
Abcam’s global supply capability and sites in key global technology hubs will then enable these reagents to be readily accessible to the wider research and diagnostic development community.
Read more
Inside Abcam's new £46million headquarters on Cambridge Biomedical Campus
